Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 5×

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079

Detection of Mutations in EGFR in Circulating Lung-Cancer Cells

Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617

Lung cancer in never smokers — a different disease

Sun, S., Schiller, J. H., & Gazdar, A. F. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2190 · Cited by 1,601

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Kim, E. S., Hirsh, V., Mok, T. S. K., Socinski, M. A., Gervais, R., Wu, Y.-L. L. C., Li, L.-Y., Watkins, C. L., Sellers, M. V., Lowe, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61758-4 · Cited by 1,241

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224

Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220

New driver mutations in non-small-cell lung cancer

Pao, W. J., & Girard, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70087-5 · Cited by 1,200

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192 · cited 2×

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013

Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor

Schlessinger, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00966-2 · Cited by 995

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961

New driver mutations in non-small-cell lung cancer

Tanoue, L. T. (2012) · Yearbook of Pulmonary Disease · doi:10.1016/j.ypdi.2012.01.036 · Cited by 833

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677

Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model

Meuwissen, R., Linn, S. C., Linnoila, R. I., Zevenhoven, J., Mooi, W. J., & Berns, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00220-4 · Cited by 643

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations

Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1643 · Cited by 643

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

Ohe, Y., Ohashi, Y., Kubota, K., Tamura, T., Nakagawa, K., Negoro, S., Nishiwaki, Y., Saijo, N., Ariyoshi, Y., & Fukuoka, M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl377 · Cited by 633

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J., Chmielecki, J., Kris, M. G., Pao, W., Ladanyi, M., & Miller, V. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2692 · Cited by 627

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Picard, S., Titier, K., Étienne, G., Teilhet, E., Ducint, D., Bernard, M., Lassalle, R., Marit, G., Reiffers, J. J., Bégaud, B., et al. (2006) · Blood · doi:10.1182/blood-2006-07-036012 · Cited by 622

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., Sgroi, D. C., Muir, B., Riemenschneider, M. J., Iacona, R. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7078 · Cited by 598

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR

Bell, D. W., Gore, I., Okimoto, R. A., Godin-Heymann, N., Sordella, R., Mulloy, R., Sharma, S. V., Brannigan, B. W., Mohapatra, G., Settleman, J., et al. (2005) · Nature Genetics · doi:10.1038/ng1671 · Cited by 529

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K. E., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M. E., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 529

Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

Su, K.-Y., Chen, H.-Y., Li, K.-C., Kuo, M.-L., Yang, J. C.-H., Chan, W.-K., Ho, B.-C., Chang, G.-C., Shih, J.-Y., Yu, S.-L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3224 · Cited by 499

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 457

Presence ofEpidermal Growth Factor ReceptorGene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer

Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., Suehisa, H., Ouchida, M., Aoe, K., Aoe, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1951 · Cited by 450

PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

Yamamoto, H., Shigematsu, H., Nomura, M., Lockwood, W. W., Sato, M., Okumura, N., Soh, J., Suzuki, M., Wistuba, I. I., Fong, K. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5084 · Cited by 443

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y.-L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203530109 · Cited by 441

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

Herbst, R. S., Sun, Y. P., Eberhardt, W., Germonpré, P. R., Saijo, N., Zhou, C., Wang, J., Li, L., Kabbinavar, F. F., Ichinose, Y., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70132-7 · Cited by 414

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature · doi:10.1038/nature09870 · Cited by 396

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Watanabe, S., Tanaka, J., Ota, T., Kondo, R., Tanaka, H., Kagamu, H., Ichikawa, K., Koshio, J., Baba, J., Miyabayashi, T., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-1 · Cited by 393

TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 359

“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases

Sun, Y., Ren, Y., Fang, Z., Li, C., Fang, R., Gao, B., Han, X., Tian, W., Pao, W. J., Chen, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6038 · Cited by 337

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Kantarjian, H. M., O'Brien, S. M., Jabbour, E. J., Garcia‐Manero, G., Quintás‐Cardama, A., Shan, J., Rios, M. B., Ravandi, F., Faderl, S. H., Kadia, T. M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-358135 · Cited by 335

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

Gong, Y., Somwar, R., Politi, K. A., Balak, M. N., Chmielecki, J., Jiang, X., & Pao, W. J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040294 · Cited by 330

Effects of smoking on the pharmacokinetics of erlotinib

Hamilton, M., Wolf, J. L., Rusk, J., Beard, S. E., Clark, G. M., Witt, K., & Cagnoni, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2235 · Cited by 312

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Rosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2158 · Cited by 304

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Huang, X., Cortes, J. E., & Kantarjian, H. M. (2012) · Cancer · doi:10.1002/cncr.26679 · Cited by 300

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Ercan, D., Xu, C., Yanagita, M., Monast, C. S., Pratilas, C. A., Montero, J., Butaney, M., Shimamura, T., Sholl, L., Ivanova, E. V., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0103 · Cited by 294

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Natale, R. B., Thongprasert, S., Greco, F. A., Thomas, M., Tsai, C., Sunpaweravong, P., Ferry, D. R., Mulatero, C., Whorf, R. C., Thompson, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5981 · Cited by 290

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

Riely, G. J., Kris, M. G., Zhao, B., Akhurst, T. J., Milton, D. T., Moore, E., Tyson, L. B., Pao, W. J., Rizvi, N. A., Schwartz, L. H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0560 · Cited by 290

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

Suda, K., Tomizawa, K., Fujii, M., Murakami, H., Osada, H., Maehara, Y., Yatabe, Y., Sekido, Y., & Mitsudomi, T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318216ee52 · Cited by 283

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

Jackman, D. M., Holmes, A. J., Lindeman, N., Wen, P. Y., Kesari, S., Borras, A. M., Bailey, C., de Jong, F., Jänne, P. A., & Johnson, B. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6126 · Cited by 260

EGFR Mutations in Small-Cell Lung Cancers in Patients Who Have Never Smoked

Zakowski, M. F., Ladanyi, M., & Kris, M. G. (2006) · New England Journal of Medicine · doi:10.1056/nejmc053610 · Cited by 254

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Janne, P. A., Wang, X., Socinski, M. A., Crawford, J., Stinchcombe, T. E., Gu, L., Capelletti, M., Edelman, M. J., Villalona-Calero, M. A., Kratzke, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1315 · Cited by 245

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Ercan, D., Zejnullahu, K., Yonesaka, K., Xiao, Y., Capelletti, M., Rogers, A. M., Lifshits, E., Brown, A., Lee, C., Christensen, J. G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.526 · Cited by 235

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

Lee, J. S., Hirsh, V., Park, K., Qin, S., Blajman, C., Perng, R.-P., Chen, Y., Emerson, L., Langmuir, P. B., & Manegold, C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1709 · Cited by 230

Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study Group

Kubota, K., Watanabe, K., Kunitoh, H., Noda, K., Ichinose, Y., Katakami, N., Sugiura, T., Kawahara, M., Yokoyama, A., Yokota, S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.114 · Cited by 230

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

Omuro, A. M. P., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N. T., Milton, D. T., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21033 · Cited by 227

Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort

Yano, S., Yamada, T., Takeuchi, S., Tachibana, K., Minami, Y., Yatabe, Y., Mitsudomi, T., Tanaka, H., Kimura, T., Kudoh, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823ab0dd · Cited by 226

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

García-Donás, J., Esteban, E., Leandro-Garcia, L. J., Castellano, D., del Alba, A. G., Climent, M. Á., Arranz, J. Á., Gallardo, E., Puente, J., Joaquim Bellmunt, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70266-2 · Cited by 223

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

Takano, T., Fukui, T., Ohe, Y., Tsuta, K., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Furuta, K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7254 · Cited by 220

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

Héon, S., Yeap, B. Y., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1588 · Cited by 217

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

Clarke, J. L., Pao, W., Wu, N., Miller, V. A., & Lassman, A. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0128-6 · Cited by 214

Chipping away at the lung cancer genome

Pao, W. J., & Hutchinson, K. E. (2012) · Nature Medicine · doi:10.1038/nm.2697 · Cited by 192

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations

Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Fujita, S., Kaji, R., Imai, Y., Monden, K., et al. (2013) · Cancer · doi:10.1002/cncr.28364 · Cited by 178

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

Yang, J. C., Schüler, M., Yamamoto, N., O'Byrne, K. J., Hirsh, V., Mok, T. S. K., Geater, S. L., Orlov, S., Tsai, C., Boyer, M. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.lba7500 · Cited by 171

Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Chang, T., Tsai, M.-F., Su, K., Wu, S.-G., Huang, C.-P., Yu, S., Yu, Y., Lan, C., Yang, C.-H., Lin, S.-B., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1440oc · Cited by 162

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib

Katayama, T., Shimizu, J., Suda, K., Onozato, R., Fukui, T., Ito, S., Hatooka, S., Sueda, T., Hida, T., Yatabe, Y., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b62572 · Cited by 161

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149

Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.

Janjigian, Y. Y., Groen, H. J. M., Horn, L., Smit, E. F., Fu, Y., Wang, F., Shahidi, M., Denis, L. J., Pao, W. J., & Miller, V. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7525 · Cited by 145

Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7521 · Cited by 145

Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers

Cheung, H. W., Du, J., Boehm, J. S., He, F., Weir, B. A., Wang, X., Butaney, M., Sequist, L. V. D., Luo, B., Engelman, J. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0046 · Cited by 131

Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

Oxnard, G. R., Miller, V. A., Robson, M. E., Azzoli, C. G., Pao, W. J., Ladanyi, M., & Arcila, M. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318250ed9d · Cited by 130

Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Goldberg, S. B., Oxnard, G. R., Digumarthy, S., Muzikansky, A., Jackman, D. M., Lennes, I. T., & Sequist, L. V. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0168 · Cited by 130

Tobacco Control in the United States--Recent Progress And Opportunities

Cokkinides, V. E., Bandi, P., McMahon, C., Jemal, A., Glynn, T., & Ward, E. M. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20037 · Cited by 124

Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report

Girard, N., Lou, E., Azzoli, C. G., Reddy, R., Robson, M. E., Harlan, M., Orlow, I., Yatabe, Y., Nafa, K., Ladanyi, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2437 · Cited by 94

Online Tool to Guide Decisions forBRCA1/2Mutation Carriers

Kurian, A. W., Muñoz, D. F., Rust, P., Schackmann, E. A., Smith, M. H., Clarke, L. D., Mills, M. A., & Plevritis, S. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6060 · Cited by 93

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

Yang, J. C., Schüler, M., Yamamoto, N., O'Byrne, K. J., Hirsh, V., Mok, T. S. K., Geater, S. L., Orlov, S., Tsai, C., Boyer, M. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.18_suppl.lba7500 · Cited by 93

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

Togashi, Y., Masago, K., Fukudo, M., Tsuchido, Y., Okuda, C., Kim, Y. H., Ikemi, Y., Sakamori, Y., Mio, T., Katsura, T., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1691-z · Cited by 79

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

Zhou, C., Wu, Y.-L. L. C., Liu, X., Wang, C., Chen, G., Feng, J., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7520 · Cited by 78

A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer

Milton, D. T., Azzoli, C. G., Heelan, R. T., Venkatraman, E. S., Gomez, J. E., Kris, M. G., Krug, L. M., Pao, W. J., Rizvi, N. A., Dunne, M., et al. (2006) · Cancer · doi:10.1002/cncr.22088 · Cited by 75

Factors Associated With the Career Choices of Hematology and Medical Oncology Fellows Trained at Academic Institutions in the United States

Horn, L., Koehler, E., Gilbert, J., & Johnson, D. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.8663 · Cited by 58

TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.

Garassino, M. C., Martelli, O., Bettini, A., Floriani, I., Copreni, E., Lauricella, C., Ganzinelli, M., Marabese, M., Broggini, M., Veronese, S. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.lba7501 · Cited by 54

EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival

Faehling, M., Eckert, R., Kamp, T., Kuom, S., Griese, U., Sträter, J., Ott, G., & Spengler, W. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.010 · Cited by 44

Drug-Induced Effects on Erlotinib Metabolism

Mir, O., Blanchet, B., & Goldwasser, F. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1105083 · Cited by 43

Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC

Rivera, V. M., Wang, F., Anjum, R., Zhang, S., Squillace, R. M., Keats, J. A., Miller, D., Ning, Y., Wardwell, S., Moran, L. E., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-1794 · Cited by 41

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.

Kris, M. G., Mok, T. S. K., Ou, S. I., Martins, R. G., Kim, D., Goldberg, Z., Zhang, H., Taylor, I. W., Letrent, S. P., & Janne, P. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7530 · Cited by 41

Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer.

Oxnard, G. R., Lo, P. C., Jackman, D. M., Butaney, M., Héon, S., Johnson, B. E., Sequist, L. V. D., & Janne, P. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7547 · Cited by 34

EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.

Rosell, R., Molina‐Vila, M. Á., Tarón, M., Bertrán-Alamillo, J., Mayo, C., Vergnenégre, A., de Marinis, F., Massutí, B., Castro, J. D., Gervais, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7522 · Cited by 28

TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.

Garassino, M. C., Martelli, O., Bettini, A., Floriani, I., Copreni, E., Lauricella, C., Ganzinelli, M., Marabese, M., Broggini, M., Veronese, S. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.18_suppl.lba7501 · Cited by 28

Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).

Goldberg, S. B., Oxnard, G. R., Digumarthy, S. R., Muzikansky, A., Jackman, D. M., Lennes, I. T., & Sequist, L. V. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7524 · Cited by 20

Abstract C189: CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations.

Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Lin, K., Dubrovskiy, A., Lee, K., Martin, T. S., Karp, R., Zhu, Z., Niu, D., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c189 · Cited by 12

Reply to G. Cai et al

Zhou, J., Hu, J., Wang, J., Wu, Y., & Fan, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4557 · Cited by 12

Discovering pathways in the tumor microenvironment important for recurrence-free survival in patients with colorectal liver metastasis.

Rhodes, T. D., Morse, M. A., Lyerly, H. K., Nevins, J. R., Clary, B. M., & Hsu, S. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.480 · Cited by 10

Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: Comparison between T790M mutation-positive and -negative populations.

Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Kaji, R., Fujita, S., Imai, Y., Monden, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7528 · Cited by 9

DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment—A catalogue of clinically relevant somatic mutations in lung cancer.

Horn, L., Chen, H., Lovly, C. M., Andrews, J., Yeh, P. S.-H., Levy, M. A., & Pao, W. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7575 · Cited by 9

Cytologic and molecular characterizations of CTC detected in patients with metastatic colorectal carcinomas.

Coget, J., Blanchard, F., Lamy, A., Touré, E., Fiore, F. D., Iwanicki–Caron, I., Michel, P., Michot, F., & Sabourin, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.485 · Cited by 8

Rare epidermal growth factor receptor (EGFR) mutations in 10,117 patients with non-small cell lung cancer (NSCLC) evaluated by the French ERMETIC IFCT network: Clinical, molecular, and survival data.

Beau‐Faller, M., Prim, N., Ruppert, A.-M., Nanni, I., Besse, B., Escande, F., Lizard, S., Prétet, J., de Crémoux, P., de Fraipont, F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.10507 · Cited by 7

Cetuximab-related skin toxicity in metastatic colorectal cancer (mCRC) patients and its correlation with molecular markers: Results from the German AIO CRC 0104 trial.

Stintzing, S., Kapaun, C., Laubender, R. P., Jung, A., Neumann, J. H. L., Modest, D. P., Giessen, C. A., Moosmann, N., Wollenberg, A., Kirchner, T., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.491 · Cited by 7

Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.

Matsusaka, S., Suenaga, M., Mishima, Y., Terui, Y., Shinozaki, E., Mizunuma, N., & Hatake, K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.486 · Cited by 6

Phase II study of EZN-2208 (PEG-SN38) with or without cetuximab in patients with metastatic colorectal cancer (CRC).

Goldberg, R. M., Garrett, C. R., Berkowitz, N. C., Bekaii‐Saab, T., Ryan, T. M., Fisher, G. A., Clive, S., Kavan, P., Shmueli, E., & Buchbinder, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.448 · Cited by 5

Treatment with EGFR tyrosine kinase inhibitors beyond progression in long-term responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival.

Faehling, M., Eckert, R., Kamp, T., Kuom, S., & Spengler, W. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7572 · Cited by 4

Two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC following complete cytoreductive surgery for colorectal carcinomatosis.

Quénet, F., Goèré, D., Mehta, S., Roca, L., Dumont, F., Essissen, M., Sain-Aubert, B., & Elias, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.4_suppl.486 · Cited by 2

Using deep sequencing of formalin-fixed paraffin embedded (FFPE) rectal cancer biopsy tissue to analyze miRNA expression in patients with rectal cancer.

Chen, Z., Gao, H., Mu, B., Wang, J., Wu, X., Qin, H., Li, W., & García‐Aguilar, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.487 · Cited by 2

Use of anti-EGFR agents among elderly patients with metastatic colorectal cancer (mCRC).

D’Silva, A., Dotan, E., Kloth, D. D., Beck, A., Cohen, S. J., & Denlinger, C. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.657 · Cited by 1

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250

The quest to overcome resistance to EGFR-targeted therapies in cancer

Chong, C. R., & Janne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,076

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

Oser, M. G., Niederst, M. J., Sequist, L. V. D., & Engelman, J. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71180-5 · Cited by 974

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms11815 · Cited by 657

Impact of EGFR mutations on treatment of non-small cell lung cancer

Johnson, B. E., Jackman, D. M., & Janne, P. A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0309-3 · Cited by 7

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

Noronha, V., Rajendra, A., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_51_19 · Cited by 64

New Treatment Strategy for Patients with EGFR -Mutant Lung Cancer

Ninomiya, T., Takigawa, N., Toyooka, S., Hotta, K., Tanimoto, M., & Kiura, K. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.63

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer

Chang, S., Chang, C., & Shih, J. (2011) · Cancers · doi:10.3390/cancers3022667 · Cited by 6

Overcoming Resistance to EGF Receptor Tyrosine Kinase Inhibitors in EGFR -mutated NSCLC

Saad, S., Huang, K., & Halmos, B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.35 · Cited by 1